Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

Shares in several pharmaceutical and biotechnology companies have fallen since President-elect Trump announced Thursday that ...

Dragged down by negative returns for shares of Amgen and Amazon.com Inc., the Dow Jones Industrial Average is declining Friday afternoon.

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply ...

The Dow Jones Industrial Average is declining Friday morning with shares of Amgen and Amazon.com Inc. delivering the stiffest headwinds for the blue-chip average.

At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

The world’s leading biotechnology company, Amgen, also recently inaugurated its GCC, which will employ 3,000 professionals.